Drugs / AZD4818
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00687232 | Jan → May 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00629239 | Jan → Jun 2008 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00687232 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 1 antagonist” CHEMBL2178570 ↗ |
| Modality | Small molecule | — CHEMBL2178570 ↗ |
| Route | Inhaled | “Dry Powder, inhalation, b.i.d., 4 weeks” NCT00629239 ↗ |
| Target | CCR1 | “C-C chemokine receptor type 1 antagonist” CHEMBL2178570 ↗ |